IMW 2021 | Metabolomics in myeloma
Rafael Fonseca
• 15 Oct 2021
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, talks on metabolomics in multiple myeloma, focusing on how our understanding of the normal biology of plasma cells has led to a better understanding of mechanisms of action of certain drugs, such as proteasome inhibitors. Immunomodulatory drugs (IMiDs) also participate in the disruption of protein metabolism; studies have shown that IMiDs can interfere with the process of detoxifying plasma cells. Dr Fonseca believes that a complete understanding of the metabolic processes will allow for more precise forms of treatment for myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
